A GLYCO HUMANIZED ANTIBODY PLATFORM WITH EMBEDDED TECHNOLOGY THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy

XENOTHERA is addressing unmet medical needs with proprietary Glyco-Humanized Antibodies:

Genetic engineering of the bio-production species
Immunogen strategy and optimization
Enhanced therapeutic efficiency of GH-pAb mix
Pharmaceutical development done and stability data for more than 2 years
Translational development program experience

Therapeutic domains:

Immunology
Multi-Drug Resistant Bacteria
Oncology
Viral infections
Others

EXECUTIVE TEAM – BOARD MEMBERS

Odile Duvaux

Chief Executive Officer

M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy DMJ Consultants

More

Bernard Vanhove

Chief Operating Officer

Ph. D., immunilogist, formerly Research Director at CNRS and INSERM, co-founder and ex-COO of Effimune

More

Françoise Shneiker

Chief Medical Officer

More

An agile company with a fast-paced development

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. It develops innovative  approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 5 years, XENOTHERA has brought to clinic its first product LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.

Pipeline

Products in development

Latest News

[Newsletter] XENONEWS

October 2021 >> Official Xenothera newsletter /Lettre d’information officielle de Xenothera << # Download our newsletter (english version). # Télécharger notre newsletter (version française)

Read more

[Press Release]Xenothera signs a memorandum of understanding with the Vietnamese conglomerate Vingroup

September 9,2021. # Download our press release (english version) # Télécharger notre communiqué de presse (version français).

Read more

[Press Release]Accelarated Scientific Advise from European Medicines Adgency EMA for Xav-19 Market Authorisation

July 8, 2021. # Download our press release (english version) # Télécharger notre communiqué de presse (version française)

Read more

Xenothera is built on a worldwide network of scientific & medical collaboration

Related scientific papers

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

B.Vanhove, S.Marot, R-T.So,B.Gaborit, G.Evanno, I.Malet, G.Lafrogne, E.Mevel, C.Ciron, P-J.Royer, E.Lheriteau, F.Raffi, R.Bruzzone, C-K.Pun Mok, O.Duvaux, A-G.Marcelin, V.Calvez

November 15, 2021

LINK

XAV-19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants

B.Vanhove, S.Marot, B.Gaborit, G.Evanno, I.Malet, C.Ciron, P-J.Royer, E.Lheriteau, S.Denié, F.Raffi, O.Duvaux, A-G.Marcelin, V.Calvez

April 5, 2021. LINK

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

Vanhove, Duvaux et al, Xenothera.

July 25, 2020 LINK

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte Immunoglobulins shows selective depletion of T lymphocytes versus Treg and Breg

Rousse et al, ESOT 2019,  Copenhagen, Denmark

LINK

Anti-Neu5Gc responses in kidney allograft recipients after treatment with Rabbit Anti-Thymocyte Globulins.

Rousse et al, ESOT 2019, Copenhaguen, Denmark

LINK

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte immunoglobulins efficiently delay skin graft rejection in non-human primate

Ciron et al, ESOT 2019,  Copenhagen, Denmark

LINK

Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients

Rousse et al, Eur J Clin Invest. 2019. Apr;49 (4)

LINK

Anti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with Anti-Thymocyte Globulin

Salama et al, 2017

LINK

Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs

Salama et al, 2017

LINK

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Reynard et al, PLoS One. 2016

LINK

Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival

Couvrat-Desvergnes et al, J Clin Invest. 2015

LINK

Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.

Salama et al, Xenotransplantation. 2015

LINK

Long-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts

Scobie et al, J Immunol. 2013

LINK

Xenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology

Investors already trusted us since 2014 by funding the company for 8M€, completed with 13M€ non dilutive financing. We are raising an additional 45M€ in 2021 to develop our pipeline with venture capital. Our products will offer a substantial patient benefit and address unsolved major public health issues
To contact us, use the form or see our full contact below

Xenothera 1 rue Vauban – 44000 Nantes – France To join us careers@xenothera.com Press Contact : IZsoGood – Ingrid Zémor ingrid@izsogood.co